Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesBYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Amylin Pharmaceuticals, 11/02/09
Amylin Pharmaceuticals, Inc., and Eli Lilly and Company announced that the U.S. Food and Drug Administration has approved an expanded indication for BYETTA injection. BYETTA is now approved for use as a stand–alone medication along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for use only in patients who were also taking other common diabetes medications and had not achieved adequate glycemic control.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Dendreon Receives FDA Acknowledgement of Complete Response
Dendreon Coproration, 11/23/09
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Companys TAP Technology
ImmunoGen, Inc., 11/20/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Glibenclamide-related excess in total and cardiovascular mortality risks: Data from large Ukrainian observational cohort study
Diabetes Research and Clinical Practice, 11/24/09
Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain
Journal of Orthopaedics and Traumatology, 11/24/09
DPP-4 Inhibitors in Clinical Practice
Postgraduate Medicine, 11/24/09
Sponsor
Article Search
Sponsor